Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S₂TOP-BLEED.

ABSTRACT:

Objective

To develop and externally validate a prediction model for major bleeding in patients with a TIA or ischemic stroke on antiplatelet agents.

Methods

We combined individual patient data from 6 randomized clinical trials (CAPRIE, ESPS-2, MATCH, CHARISMA, ESPRIT, and PRoFESS) investigating antiplatelet therapy after TIA or ischemic stroke. Cox regression analyses stratified by trial were performed to study the association between predictors and major bleeding. A risk prediction model was derived and validated in the PERFORM trial. Performance was assessed with the c statistic and calibration plots.

Results

Major bleeding occurred in 1,530 of the 43,112 patients during 94,833 person-years of follow-up. The observed 3-year risk of major bleeding was 4.6% (95

SUBMITTER: Hilkens NA 

PROVIDER: S-EPMC5683104 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature